To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
24 Current news of CureVacrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Study conducted in Peru and Panama
CureVac N.V. announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV. The dose-confirmation study, entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants in two distinct ...
Further COVID-19 Vaccine Development and Production Capacity Expansion
CureVac N.V. has received notification from the German Federal Ministry of Education and Research (BMBF) that CureVac is expected receive up to 252 million euros to support the development of its COVID-19 vaccine candidate. In July 2020, CureVac had applied to a grant as part of a special program ...
Dr. Igor Splawski as Chief Scientific Officer appointed
CureVac announced that Dr. Franz-Werner Haas, previously acting Chief Executive Officer and Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO). Before Dr. Haas joined CureVac in June 2012, he worked as Vice President Operations and Chief Compliance Officer of SYGNIS ...
CureVac AG announced the closing of its latest private financing round, raising a total of USD 640 million (560 million Euros). The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau (KfW) with USD 343 million and GSK ...
Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases
GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements ...
Trial will start promptly and will be conducted in Germany and Belgium
CureVac AG announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and ...
Federal Government will not influence corporate policy decisions
The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the ...
First phase 1/2a clinical trial in healthy volunteers in June 2020 planned
CureVac AG announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2). The data showed a fast induction of a balanced immune response with high levels of virus neutralizing titers (VNTs) and T-cell responses. VNTs are a major ...
Company focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide
CureVac AG confirmed that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide. As a consequence, the company is in contact with especially CEPI and many other organizations and authorities worldwide, ...
CureVac AG announced that company founder and Chairman of the Supervisory Board Ingmar Hoerr is replacing Daniel Menichella in his function as Chief Executive Officer (CEO). "On behalf of the Supervisory Board I would like to thank Dan Menichella very much for the great contributions he has done ...